[go: up one dir, main page]

WO2008057464A3 - Compositions and methods for improving the bioavailability of liothyronine - Google Patents

Compositions and methods for improving the bioavailability of liothyronine Download PDF

Info

Publication number
WO2008057464A3
WO2008057464A3 PCT/US2007/023220 US2007023220W WO2008057464A3 WO 2008057464 A3 WO2008057464 A3 WO 2008057464A3 US 2007023220 W US2007023220 W US 2007023220W WO 2008057464 A3 WO2008057464 A3 WO 2008057464A3
Authority
WO
WIPO (PCT)
Prior art keywords
liothyronine
compositions
bioavailability
improving
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/023220
Other languages
French (fr)
Other versions
WO2008057464A2 (en
Inventor
Michael Lamson
M King Jolly
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
King Pharmaceuticals Research and Development Inc
Original Assignee
King Pharmaceuticals Research and Development Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by King Pharmaceuticals Research and Development Inc filed Critical King Pharmaceuticals Research and Development Inc
Publication of WO2008057464A2 publication Critical patent/WO2008057464A2/en
Publication of WO2008057464A3 publication Critical patent/WO2008057464A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention is directed to sustained release pharmaceutical compositions that include a thyroid hormone, such as liothyronine or a pharmaceutically acceptable salt thereof. More specifically, the present invention is directed to sustained release pharmaceutical compositions that include liothyronine, or a pharmaceutically acceptable salt thereof that are capable of maintaining the plasma concentration of liothyronine above the baseline concentration over an extended period of time while mitigating or even eliminating the initial, acute plasma concentration peak of liothyronine, characteristic of immediate release formulations.
PCT/US2007/023220 2006-11-01 2007-11-01 Compositions and methods for improving the bioavailability of liothyronine Ceased WO2008057464A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85618406P 2006-11-01 2006-11-01
US60/856,184 2006-11-01

Publications (2)

Publication Number Publication Date
WO2008057464A2 WO2008057464A2 (en) 2008-05-15
WO2008057464A3 true WO2008057464A3 (en) 2008-10-02

Family

ID=39273086

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/023220 Ceased WO2008057464A2 (en) 2006-11-01 2007-11-01 Compositions and methods for improving the bioavailability of liothyronine

Country Status (1)

Country Link
WO (1) WO2008057464A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109475605A (en) * 2016-05-03 2019-03-15 斯佩特里克斯治疗有限公司 Compositions and methods for providing thyroid hormones or analogs thereof
KR20180132955A (en) * 2016-05-03 2018-12-12 스펙트릭스 테라퓨틱스, 엘엘씨 Compositions and methods for providing thyroid hormones or analogs thereof
US10695309B2 (en) 2017-03-31 2020-06-30 Western New England University Sustained-release liothyronine formulations, method of preparation and method of use thereof
ES2982082T3 (en) 2020-01-13 2024-10-14 Amneal Complex Products Res Llc Sustained release compositions comprising liothyronine
WO2022260888A1 (en) 2021-06-08 2022-12-15 Amneal Complex Products Research Llc Sustained release compositions comprising liothyronine

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006105482A2 (en) * 2005-03-31 2006-10-05 King Pharmaceuticals Research & Development, Inc. Controlled release pharmaceutical compositions of liothyronine and methods of making and using the same
WO2007030577A2 (en) * 2005-09-08 2007-03-15 Shire Llc Prodrugs of t3 and t4 with enhanced bioavailability
WO2007068948A2 (en) * 2005-12-15 2007-06-21 Archimedes Development Limited Pharmaceutical sustained release compositions comprising in particular thyroid hormones

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006105482A2 (en) * 2005-03-31 2006-10-05 King Pharmaceuticals Research & Development, Inc. Controlled release pharmaceutical compositions of liothyronine and methods of making and using the same
US20060246133A1 (en) * 2005-03-31 2006-11-02 Beasley Martin W Controlled release pharmaceutical compositions of liothyronine and methods of making and using the same
WO2007030577A2 (en) * 2005-09-08 2007-03-15 Shire Llc Prodrugs of t3 and t4 with enhanced bioavailability
WO2007068948A2 (en) * 2005-12-15 2007-06-21 Archimedes Development Limited Pharmaceutical sustained release compositions comprising in particular thyroid hormones

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LEGGIO G M ET AL: "Comparative bioavailability of different formulations of levothyroxine and liothyronine in healthy volunteers", JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, vol. 29, no. 11, December 2006 (2006-12-01), pages RC35 - RC38, XP002489747, ISSN: 0391-4097 *

Also Published As

Publication number Publication date
WO2008057464A2 (en) 2008-05-15

Similar Documents

Publication Publication Date Title
WO2007087431A3 (en) Sublingual fentanyl spray
WO2010065709A3 (en) Hydroxamic acid derivatives, preparation and therapeutic uses thereof
WO2008063910A3 (en) Method of preparing solid dosage forms of multi-phasic pharmaceutical compositions
WO2009017837A3 (en) Sublingual fentanyl spray
WO2009114118A3 (en) Oral pharmaceutical compositions of buprenorphine and method of use
WO2009066326A3 (en) Improved process for the preparation of prasugrel and its pharmaceutically acceptable salts
WO2008053297A3 (en) Pharmaceutical compositions comprising entacapone, levodopa, and carbidopa
WO2008066899A3 (en) Nanoparticulate formulations and methods for the making and use thereof
WO2007146248A3 (en) Stable laquinimod preparations
WO2008148074A3 (en) Inhibitors of mtor and methods of treatment using same
TW200633716A (en) Compositions and methods for stabilizing active pharmaceutical ingredients
JO2973B1 (en) Fumarate Salt Of (alphaS, betaR)-6-Bromo-alfa-[2-(dimethylamino)ethyl]-2- Methoxy-alpha-1-naphthalenyl-beta-phenyl-3- Quinolineethanol
ZA200806778B (en) N-Hydroxyacrylamide compounds
UA93709C2 (en) 12-imidazolyl-1-dodecanol and use thereof in the preparation of pharmaceutical compositions
WO2008033888A3 (en) Methods for administering long-lasting hypoglycemic agents
WO2009060952A1 (en) Novel preparation
WO2009041787A3 (en) Pharmaceutical composition comprising inhibitors of cell adhesion molecule isolated from piper nigrum for the prevention and treatment of inflammatory disease
WO2008035380A3 (en) An improved process for the preparation of high purity formoterol and its pharmaceutically acceptable salts
WO2008057464A3 (en) Compositions and methods for improving the bioavailability of liothyronine
WO2008104852A3 (en) Pharmaceutical compositions comprising adsorbate of fenofibrate
WO2011056630A3 (en) Small molecule inhibitors of hepatitis c virus
WO2006130703A3 (en) Modified release formulations of anti-irritability drugs
UA97348C2 (en) HETEROCYCLIC NF-kB INHIBITORS
WO2008081268A3 (en) Pharmaceutical compositions of entacapone
WO2007110765A3 (en) Processes for the preparation of octreotide

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07861687

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07861687

Country of ref document: EP

Kind code of ref document: A2